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With increasing life expectancy and improved surgical
technology an ever-larger number of elderly patients with
cardiovascular disease, or signi®cant cardiovascular risk
factors will undergo major surgery. More than 5% of an
unselected surgical population undergoing non-cardiac
surgery will suffer from perioperative cardiovascular com-
plications including myocardial infarction and cardiac
death. The incidence of adverse cardiac events may even
reach 30% in high-risk patients undergoing vascular surgery
causing a substantial ®nancial burden of perioperative
health care costs.59 Thus, all therapeutic measures should be
undertaken to reach the challenging goal of a lower
incidence of perioperative cardiovascular complications.
Gaining control over sympathetic nervous system
activity, that is blunting the adrenergic response to the
surgical trauma, traditionally represents an important aspect
of anaesthetic practice.21 Anaesthesiology has been regar-
ded as the `practice of autonomic nervous system medicine'.
While variable and moderate changes in sympathetic
nervous system activity function as a servo-control mechan-
ism and are even required to maintain and optimize cardiac
performance, undue liberation of excitotoxic substances
such as catecholamines and in¯ammatory cytokines, par-
ticularly during emergence from anaesthesia and the painful
postoperative period, facilitates the occurrence of cardio-
vascular complications.83 84 At this point, the life-support-
ing adrenergic drive (`®ght-or-¯ight-response') turns into a
potentially hazardous life-threatening maladaptation. In
support of this concept, the bene®cial effects of anti-
adrenergic treatment regimens in perioperative medicine
have been con®rmed, in observational studies, meta-
analyses5 51 66 and randomized controlled clinical
trials.43 54 59 63 80 84 However, the seemingly established
concept of `sympatholysis' as an effective cardioprotective
treatment modality needs considerable re®nement in the
light of the many new experimental and clinical ®ndings.
The parlance of `sympatholytic' protection erroneously
equates annihilation of any type of adrenergic stimulation
with cardioprotection and should be replaced by `sympatho-
modulatory'protection.
The present review summarizes ®ndings from large-scale
heart failure trials and discusses basic and clinical aspects of
individual sympatho-modulatory therapies, as currently
used in perioperative medicine, including b-adrenergic
antagonism, a2-agonism, and regional anaesthetic tech-
niques. For limitation of space, reviews will often be cited
where further references to the primary literature may be
found.
Adrenergic activity in the heart:
a double-edged sword
Changing therapeutic paradigms: a historical
perspective
Over several decades, the basic ideas on the role of the
sympathetic nervous system in healthy and diseased
myocardium have required repeated re-evaluation. In
1960, Braunwald and colleagues at the National Institutes
of Health reported for the ®rst time on adrenergic
dysfunction in the failing heart. Based on reduced
noradrenaline levels in failing myocardial tissue and the
adverse short-term effects of high doses of anti-adrenergic
agents,25 it became widely accepted that suf®cient andÐin
the case of heart failureÐsupportive adrenergic drive would
be needed to ensure normal cardiac function. Fifteen years
later in the late 1970s, this therapeutic concept was
challenged by the following ®ndings summarized in
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reference13. First, chronically administered b-adrenergic
antagonists (b-AAs) exhibited bene®cial effects in idio-
pathic dilated cardiomyopathies. Secondly, b-adrenergic
receptor (b-AR) down-regulation was detected in failing
myocardium as a consequence of excessive adrenergic
drive. Thirdly, despite decreased noradrenaline stores in
failing myocardial tissue, coronary sinus blood exhibited
increased noradrenaline release. These ®ndings led to a new
`counterintuitive' therapeutic strategy whereby anti-adre-
nergic treatment was considered bene®cial in the failing
heart. This concept has dominated therapeutic thinking in
cardiology for almost 20 years. However, most recent
results from basic science and clinical studies again
questioned this `dogma' and called for further re®nement
of the concept.12 First, moxonidine, a centrally active
imidazoline agonist, which lowers noradrenaline spill-over
in myocardial tissue and even reverses catecholamine-
induced remodelling in the myocardium, increased mortal-
ity by more than 50% in the Moxonidine Congestive Heart
Failure Trial (MOXCON).17 This is in accordance with
experimental results from a canine heart failure model
where dopamine b-hydroxylase inhibition resulting in
decreased noradrenaline levels did not improve left
ventricular function.69 Secondly, in the b-Blocker
Evaluation of Survival Trial (BEST), bucindolol increased
mortality disproportionately in black NYHA Class IV
patients, although the overall bene®t of bucindolol still
prevailed in the whole bucindolol cohort when compared
with placebo.6 It was speculated that pronounced b2-AR
antagonism, which excessively decreases pre-synaptic
noradrenaline release, in conjunction with unopposed a1-
block could be responsible for the observed adverse effects.
Collectively, these ®ndings seriously challenged the overly
simple dogma of `sympatholytic equals bene®cial'.
Irreversible removal of adrenergic support with the inability
to recruit compensatory adrenergic drive when required to
maintain adequate cardiac function is obviously detri-
mental. Moreover, these observations highlight the funda-
mentally differential biological consequences between
`unselective inhibition of adrenergic drive', which may be
achieved by central inhibition of the sympathetic tone vs
selective peripheral receptor-targeted block.
Implications for perioperative medicine
Hyperadrenergic drive is a hallmark of the perioperative
stress response. Maladaptive alterations in the autonomic
nervous system, such as down-regulation of adrenergic
receptors and autonomic imbalance, persist for weeks after
surgery.1 Activation of the sympathetic nervous system,
particularly b-ARs dramatically increases heart rate and
oxygen consumption, and plays a central role in the
development of perioperative ischaemia. Patients with
coronary artery disease, risk factors for coronary artery
disease or speci®c genetic polymorphisms may be particu-
larly sensitive to catecholamine toxicity and prone to
perioperative ischaemia and cardiac complications. Current
knowledge suggests signi®cant protection from maladaptive
adrenergic activity by selective inhibition and/or activation
of speci®c b/a-AR subtypes.83 Identi®cation of patients
with critical genetic polymorphisms associated with adverse
outcome as part of perioperative risk assessment may
directly improve patient management by adequate timely
pharmacological interventions and decrease perioperative
mortality. Unfortunately, at present the pharmacological
armamentarium is still limited with respect to receptor-
subtype selectivity. Pan-adrenergic inhibition of the sym-
pathetic nervous system may not represent the optimal
cardioprotective treatment modality in perioperative medi-
cine. Irreversible removal of adrenergic support with the
inability to maintain adequate cardiac function may be
detrimental.
Sympatho-modulation by medication
Alpha2-agonists and the cardiovascular system
Basic mechanisms and cardiovascular effects
a2-Agonists exert their cardioprotective effects predomin-
antly by attenuation of catecholamine release and thus
inhibition of stress-induced tachycardia. The hypotensive
effect of this class of drugs is achieved by lowering central
sympathetic tone via activation of a2A-ARs and the
pharmacologically less well-de®ned imidazoline1 recep-
tors. This is consistent with the notion that clonidine is
ineffective in controlling increased arterial pressure in
hypertensive tetraplegic patients.44 In contrast, bradycardic
effects are elicited by vagomimetic effects, and are
preserved in tetraplegic patients.64 Apart from their
haemodynamic effects, a2-agonists may induce analgesia
(particularly for sympathetically maintained pain), anxio-
lysis, and sedation.32 34 Post-junctional a2B-ARs mediate
the short-term hypertensive response seen with these drugs
via stimulation of L-type Ca2+ channels in smooth muscle
cells of resistance vessels. Recently, etomidate was found to
activate a2B-ARs thereby eliciting its well-known stabiliz-
ing cardiovascular effect.55 Pre-junctional a2A-ARs have
anti-adrenergic effects, and post-junctional a2A-ARs have
anaesthetic effects via inhibition of L-type Ca2+ channels in
neurons localized in the locus coeruleus and nucleus
reticularis lateralis. Decreased ganglionic transmission and
a concomitant increase of the counterregulatory vagal tone
can further enhance the central effects of a2-agonist.45
Interestingly, the anti-arrhythmic effects of a2-agonists are
completely mediated via the vagal nerve, as anti-arrhythmic
effects are totally abolished by vagotomy.30 One of the
potential advantages of central inhibition of sympathetic
tone over peripheral receptor block is that the release of co-
transmitters such as neuropeptide-Y, a major contributor to
coronary vascular resistance, is equally suppressed. On the
other hand, these neurotransmitters may exert trophic
effects on cardiomyocytes. All a2-agonists interact with
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imidazoline receptors because of their imidazole ring.
Although the novel a2-agonist moxonidine was developed
to preferentially interact with imidazoline binding sites, it
requires the a2-AR to lower arterial pressure as no
hypotensive effects in response to moxonidine were
observed in a2-AR knockout mice.78 As with b-ARs,
a-ARs can be up- or down-regulated.74 However, their
regulation and the subsequent physiological consequences
are poorly understood. Unfortunately, there are no subtype-
selective agonists clinically available. At present, the most
commonly used a2-agonists are clonidine and dexmedeto-
midine. Their relative receptor speci®cities as compared
with other a2-agonists are listed in Table 1.
Clinical aspects and considerations
A recent meta-analysis on the ef®cacy of clonidine for the
prevention of perioperative myocardial ischaemia included
seven studies and concluded that clonidine reduces cardiac
ischaemic events in patients who either have or are at risk of
coronary artery disease, without increasing the incidence of
bradycardia.51 Interestingly, this meta-analysis found a
reduction in myocardial ischaemia by clonidine in cardiac
and non-cardiac surgery, but only in the oral (mostly
preoperative), but not the i.v. administration group.
Mortality associated with myocardial ischaemia was not
evaluated in this meta-analysis because of the expected low
number of myocardial infarctions and cardiac deaths.
Another recent meta-analysis included studies with all
a2-agonists claimed a lower cardiac morbidity in high-risk
patients undergoing vascular and major surgery.82
Clonidine has also been found to decrease anaesthetic-
induced impairment of the barore¯ex responses and thus to
attenuate arterial pressure lability (smaller haemodynamic
¯uctuations around a lower basal arterial pressure).57
Similarly, perioperative mivazerol has been reported to
decrease the occurrence of perioperative ischaemic events,
and recently to decrease cardiac death (9.5 vs 14% in
placebo, P=0.02), but not myocardial infarction, in patients
with coronary artery disease undergoing vascular surgery.54
However, there was no effect of mivazerol on the incidence
of all-cause deaths, cardiac deaths, or myocardial infarc-
tions in the whole cohort of study patients (undergoing all
types of surgery). There is currently less evidence for
a2-agonists than b-AA to decrease perioperative cardio-
vascular mortality. However, apart from their cardio-
vascular effects, a2-agonists may exert indirect bene®cial
cardiac effects by their non-ceiling analgesic, anti-shiver-
ing, and sedative effects. Sudden discontinuation should be
avoided because of the risk of withdrawal syndrome.83
Theoretically, a2-agonists can jeopardize coronary ¯ow
reserve, as intracoronary application of a2-antagonist
yohimbine was shown to attenuate inhibition of coronary
¯ow in patients undergoing coronary culprit lesion stent-
ing.27 Conversely, a-adrenergic vasoconstriction reduces
systolic retrograde coronary blood ¯ow maintaining suf®-
cient perfusion in subendocardial myocardium during
adrenergic stimulation.48 Bradycardia as a side-effect
should be primarily treated with atropine, but higher doses
of clonidine can markedly blunt the effect of atropine.49
Conversely, clonidine may signi®cantly potentiate the
pressor effects of catecholamines.50 At higher concentra-
tions, a2-agonists may promote coagulation.79 Although
detrimental cardiac effects were reported after long-term
use of a2-agonists in heart failure patients, the short-term
use of a2-agonists at moderate doses (thrombotic complic-
ations are possible with high doses) in perioperative
medicine can be advocated. Nonetheless, more selective
modulation of a2-ARs would be highly desirable.
b-AAs and the cardiovascular system
Basic mechanisms and cardiovascular effects
Although some effects of b-AAs may be caused by central
actions,72 85 b-AAs in principle mediate their effects
directly at the end-organ receptor level by decreasing
b-AR signalling. This is fundamentally different from most
of the a2-agonist-mediated effects. Important mechanisms
responsible for b-AA-mediated perioperative cardioprotec-
tion are:83
d Blunting of stress-induced increases in heart rate
optimizing myocardial oxygen balance and stabilizing
atherosclerotic plaques.
d Improved Ca2+ handling and bioenergetics shifting ATP
production from oxidation of free fatty acid to less
oxygen consuming glucose oxidation.
d Prevention of target protein hyperphosphorylation lead-
ing to decreased receptor desensitization and diastolic
Ca2+ leackage by the ryanodine receptor.
d Inhibition of b1-AR-mediated cytotoxicity (altered gene
expression, mechanical unloading, apoptosis, necrosis).
d Anti-arrhythmic effects.
Table 1 a2-Agonists and speci®c properties. +=effect present; I1*=centrally located imidazoline receptor-1; /=not known
Drug Selectivity ratio
of a2/a1
Selectivity ratio
of a2/I1*
Plasma
half-life
Lipid
solubility
Clearance Special
Clonidine 40 16 9 h + Hepatic/renal
}
Sedative
Mivazerol 400 215 4 h + Hepatic/renal Analgesic
Dexmedetomidine 1600 30 2 h + Hepatic/renal Anti-shivering
Moxonidine / 70 2 h + Hepatic/renal Anti-sialogue
Neuromuscular blocking agents
Sympatho-modulation in perioperative medicine
55
In contrast to a2-agonists, untoward peripheral effects of
b-AAs can be offset by counter-regulatory production of
endogenous catecholamines explaining the good tolerability
of this class of drugs.26 43 59 84 On the other hand, direct
receptor block may be more cytoprotective under supra-
maximal autonomic stimulation (¯at part of the sigmoid
dose±response curve) than simply lowering catecholamine
levels as observed with a2-agonist treatment. Finally,
selective inhibition of the b1-AR-mediated toxic effects
leaves the bene®cial effects of moderate b2-AR-stimulation
unaffected and thus may further improve haemodynamic
tolerance.83 Notably, b1-AR antagonism enhances inotropic
response to b2-AR stimulation.29 b1-AR-block may increase
post-ischaemic and pharmacologic coronary ¯ow velocity
reserve.7 Although many ancillary properties of individual
b-AAs are thought to be linked to clinical effectiveness and
tolerability,75 their signi®cance in perioperative medicine
needs to be elucidated. The selection of a speci®c agent over
another on the basis of individual drug pro®les may be
advantageous in speci®c clinical situations (Table 2). As
with clonidine, b-AAs improve the barore¯ex sensitivity in
elderly hypertensive patients, thus stabilizing arterial
pressure.16
Clinical aspects and considerations
The evidence for the effectiveness of b-AAs in reducing
perioperative cardiac events has been extensively re-
viewed.2 62 Based on the clinical evidence of mainly two
well-designed randomized clinical trials,43 59 the periopera-
tive use of b-AAs has been ®rmly supported in the updated
(2002) guidelines on perioperative evaluation of patients
undergoing non-cardiac surgery of the American Heart
Association (AHA).20 Mangano and colleagues showed in a
cohort of elderly male patients with coronary artery disease
or at risk of coronary artery disease undergoing major
surgery (predominantly abdominal and vascular) that
perioperative atenolol administration decreased long-term
overall mortality by 55% and cardiac mortality by 65%.43
Comparing bisoprolol with standard care, Poldermans and
colleagues demonstrated a 10-fold reduction in the 30-day
perioperative incidence of cardiac death and non-fatal
myocardial infarction in patients with positive dobutamine
stress echocardiography undergoing vascular surgery.59
Although these randomized clinical studies have been
extensively criticized on a number of grounds,42 62 b-AA
treatment represents undoubtedly the most effective treat-
ment modality to prevent perioperative cardiac complica-
tions. According to the AHA guidelines, all patients with
chronic b-AA treatment, or de®nite coronary artery disease
undergoing major vascular surgery should be treated with
perioperative b-AAs (Class I evidence for b-AAs). All other
indications for the preventive use of perioperative b-AAs
are less well supported by current evidence and need further
clari®cation in randomized clinical studies.36 In a recent
editorial accompanying an article by London and col-
leagues42 on the physiologic foundations and clinical
controversies of perioperative b-AA treatment, Kertai and
colleagues33 recommended the widespread use of peri-
operative b-AA treatment in all surgical patients with only a
single risk factor as well as the long-term continuation of
such a treatment after surgery. We would like to stress,
however, that such type of high-impact recommendations
should be based on more solid facts, namely randomized
controlled trials. In no case should these suggestions hinder
necessary future research in this important area and render
the conduct of randomized controlled trials evaluating
perioperative b-AA treatment impossible because of unjus-
ti®ed ethical objections and/or misperceptions about the
currently available evidence.
Patients with chronic b-AA treatment may need substan-
tial perioperative supplementation. The currently recom-
mended use of atenolol, bisoprolol, and metoprolol is
remarkably cheap and safe if cautiously titrated.70
Whenever bradycardia occurs, it is important to decide
whether discontinuation of treatment is really necessary.
Although titration of b-AAs to individual ischaemic
thresholds using non-invasive stress tests appears rational,
particularly with respect to side-effects,63 it is hardly
applicable in the clinical setting (too expensive, many
patients with pre-existing ST-segment changes or left-
bundle branch block). Also, the arti®cial conditions during
non-invasive stress tests cannot entirely simulate the real
Table 2 b-AAs and ancillary properties. NO, nitric oxide; +=effect present; ±=effect absent; ?=still under debate
Drug Selectivity ratio
of b1/b2
Membrane
stabilizing
activity
Intrinsic sympatho-
mimetic activity
Lipid
solubility
Clearance Special
Propranolol 2.1 + ± +++ Hepatic Inverse agonist
Metoprolol 74 ± ± + Hepatic stereoselective Inverse agonist-AR
Atenolol 75 ± ± ± Renal ±
Esmolol 70 ± ± ± Erythrocyte esterase ±
Bisoprolol 119 ± ± (+) Hepatic/renal ±
Celiprolol ~300 ± b2+ ± Hepatic/renal b2-agonist
Nebivolol 293 ± ± + Hepatic NO-release bronchodilation
Carvedilol 7.2 ± b1+(?) + Hepatic, stereo-selective Anti-oxidant, anti-adhesive. a1-antagonist, b-AR¯
Bucindolol 1.4 ± + (?) + Hepatic a1-antagonist
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perioperative conditions with signi®cant changes in coagu-
lation and cytokine release. b-AAs should be initiated as
early as possible (ideally weeks before surgery), maintained
for at least 1 week up to 1 month (in vascular patients), and
tapered before discontinuation to avoid adrenergic with-
drawal response. In no case should administration of b-AAs
serve to circumvent important preoperative risk strati®ca-
tion or possible invasive interventions.23 Responses of a-
and b-AR may be altered by down-regulation and
desensitization in sepsis, burns, cirrhosis, haemorrhagic
shock, and cardiopulmonary bypass.74 Polymorphic
metabolism of b-AA may signi®cantly affect clinical
responsiveness. Accordingly, poor metabolizers with dif-
ferent variants of CYP23D6 (cytochrome P450 isoform)
may have increased plasma levels of metoprolol.31 This is
not the case for bisoprolol, which is independent of any
genetic polymorphism of oxidation.38 Genetic background
also appears to be responsible for observed variability in
ef®ciency of b-AA treatment in black and Asian patients.6
Finally, b-AAs are of questionable value in heart failure
patients with atrial ®brillation.24 Thus, one can speculate
that their perioperative administration in cardiac risk
patients with atrial ®brillation might be of minimal or no
advantage. Importantly, coronary artery disease represents a
severe in¯ammatory process affecting the whole coronary
tree (`pancoronaritis'). As the localization of perioperative
myocardial infarction is related only in 50% to the culprit
coronary lesion or the site of the most critical coronary
stenoses,18 preoperative invasive interventions such as
angioplasty or coronary surgery may not replace but rather
complete the protection afforded by perioperative b-AA
treatment. Whether the protection by perioperative b-AA
treatment can be enhanced by additional administration of
statins, must be evaluated in future randomized controlled
trials. Perioperative b-AA treatment should be used in
accordance with available data obtained from perioperative
randomized controlled trials. Recent ®ndings from peri-
operative randomized clinical trials offer a strong founda-
tion for b-AA-mediated cardioprotection.
Sympatho-modulation by regional
anaesthesia/analgesia
General comments
Approximately one-third of patients undergo regional
anaesthesia for surgery. The anaesthetic and analgesic
power of epidural anaesthesia has been recently reinforced
by reports on coronary artery bypass grafting in awake
patients under epidural anaesthesia.3 In general, regional
anaesthesia more effectively decreases the neurohumoral
response to surgery than general anaesthesia, particularly
with respect to the release of adrenal cortical and medullary
hormones. Although some meta-analyses claim regional
anaesthesia/analgesia to be superior to general anaesthesia
with respect to cardiovascular and other outcome measures
(deep vein thrombosis, pulmonary embolism, transfusion
requirements, pneumonia and other infections, respiratory
failure, renal failure, stroke),4 5 66 most large-scale random-
ized trials clearly demonstrated that the choice of anaes-
thesia does not in¯uence cardiac morbidity and
mortality.52 56 58 65 Hence, based on the currently available
clinical data, the opinion prevails that factors other than type
of anaesthesia are more important for cardiac outcome in
even high-risk patients. However, uncertainty about the
ultimate net bene®ts of regional anaesthesia compared with
general anaesthesia remains.
Spinal anaesthesia
Basic mechanisms and cardiovascular effects in spinal
anaesthesia
Block of sympathetic nerves (T1-L2, cardiac accelerator
nerves T1-T5) can lead to sudden profound physiological
changes during spinal anaesthesia. A rapid distribution of
the local anaesthetic in the subarachnoidal space results in
the block of all ®bres of the anterior and posterior spinal
roots including the sympathetic afferent and efferent ®bres.
Spinal cord penetration of the local anaesthetic may be also
responsible for speci®c anaesthetic effects. The short
diffusion path to small diameter B- and C-®bres makes
them speci®cally susceptible to local anaesthetic action.
Much more than in epidural anaesthesia/analgesia, the
degree of sympathetic denervation is often unpredictable
and quite extensive, albeit for a relatively limited time.
Importantly, the level of sympathetic block exceeds that of
the sensory block usually by two dermatomes, but may be
more than six dermatomes.15 The level of the block depends
on age and position of the patient. Levels above T1 not only
decrease venous return and thereby slow heart rate, but also
abolish completely the sympathetic cardiac drive.
Hypotension in spinal anaesthesia is predominantly a result
of the marked decrease in venous return followed by a
decrease in cardiac output (reduced by 20%) and stroke
volume (reduced by 25%). Systemic vascular resistance
nearly remains unaffected (±5%), that is there is minimal
arteriolar dilation. In contrast to general anaesthesia, no
down-regulation of lymphocyte b-ARs was observed after
Caesarean section when performed under spinal anaesthe-
sia. The bene®cial effects on b-AR-preservation, stress
response, and haemodynamics were also recently shown in
patients undergoing coronary artery bypass grafting with a
high spinal anaesthesia as an adjunct to general
anaesthesia.37
Clinical aspects and considerations in spinal anaesthesia
The incidence of cardiac arrest in spinal anaesthesia is
signi®cant (estimated at 1:10 000) and is thought to be
mainly a result of sympatho-vagal dysbalance.14 Risk
factors for cardiac arrest under spinal (and epidural)
anaesthesia are: male gender, heart rate less than 60 beats
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min±1, ASA Physical Status-I (i.e. healthy individuals),
b-AA use, age less than 50 yr, and sensory levels above
T6.14 60 Marked hypotension may occur in 30% and
bradycardia in 15% of patients. Pre-hydration, slow injec-
tion of the local anaesthetic, and unilateral block may help
to decrease adverse haemodynamic effects.40 Incremental
continuous spinal anaesthesia may provoke signi®cantly
less hypotensive episodes and ischaemic cardiac events than
bolus injection.22 Cardiovascular side-effects may occur at
any time during spinal anaesthesia and even develop hours
after surgery.61 Overall, the sympathetic denervation
achieved by spinal anaesthesia is fairly unpredictable,
rather transient (except for continuous spinal anaesthesia),
and associated with a remarkably high incidence of
haemodynamic instability and cardiac arrest.
Epidural anaesthesia/analgesia
Basic mechanisms and cardiovascular effects
The dorsal and ventral roots are the primary sites of action in
epidural anaesthesia. However, local anaesthetics can also
cross the dura and penetrate the spinal cord. In general,
sensory anaesthesia is established before a sympathetic
block suf®cient to induce systemic hypotension. Changes in
arterial pressure, heart rate, and cardiac output re¯ect the
level of the block, but are in general less pronounced than in
spinal anaesthesia. Below T5, there is rarely hypotension as
compensatory vasoconstriction in unblocked segments
occurs. In other words, the vasodilation below the level of
sympathetic block is usually compensated for by vasocon-
striction above the level of block, such that the decrease in
arterial pressure is relatively mild. Above T5, cardiac ®bres
may be affected and no compensatory vasoconstriction may
occur leading to marked hypotension, particularly in
hypovolaemic patients.11 Levels up to T10 increase the
lower limb blood ¯ow, but do not change coronary blood
¯ow, provided there is no decrease in arterial pressure.73
High levels (>T5) cause a decrease in coronary blood ¯ow
by up to 50% and an increase in coronary vascular
resistance. However, as myocardial work is concomitantly
decreased to a greater degree (decreased heart rate and
contractility), no adverse effects may be seen. Hypotension
in lumbar epidural anaesthesia may have opposite effects on
cardiac oxygen balance. Compensatory re¯ex activity in
unblocked thoracic sympathetic segments may decrease
coronary blood supply and provoke wall motion abnorm-
alities.68 Hypotension in lumbar epidural anaesthesia (T6-
T12) may be therefore more critical in susceptible patients.
However, lumbar and thoracic epidural anaesthesia have
both been reported to decrease left ventricular loading and
improve global and regional ventricular function in patients
with coronary artery disease. Thoracic epidural anaesthesia
additionally increases the diameter of stenotic coronary
arteries.9 As with b-AA treatment, there is a redistribution
from the epicardial to the endocardial blood ¯ow in thoracic
epidural anaesthesia.35 The use of thoracic epidural
anaesthesia decreases ST-segment changes and infarct size
after coronary artery occlusion and may improve post-
ischaemic functional recovery (less stunning).47
Clinical aspects and considerations in epidural anaesthe-
sia/analgesia
Thoracic epidural anaesthesia was reported to be effective
in humans with myocardial ischaemia refractory to con-
ventional medical treatment indicating that under speci®c
conditions thoracic epidural anaesthesia may be superior to
anti-anginal medication.3 Although some studies claim that
the use of epidural anaesthesia with or without general
anaesthesia would improve perioperative cardiac outcome,
there is currently little evidence from large-scale random-
ized controlled trials to support this view. Disappointingly, a
large multicentre, randomized, unblinded study with 973
patients was unable to detect decreased 30-day mortality in
patients undergoing abdominal surgery with epidural
(thoracic or lumbar)/general anaesthesia plus postoperative
epidural analgesia vs general anaesthesia alone.56 These
®ndings reiterate the observations made by other investiga-
tors.53 81 However, postoperative epidural analgesia was
found to signi®cantly improve pulmonary outcome in a
recent meta-analysis.4 Pulmonary dysfunction, stroke, acute
renal failure, and acute confusion were also less frequently
observed in patients undergoing coronary artery bypass
graft surgery when receiving postoperative thoracic epidural
analgesia.71 By inhibition of sympathetic spinal re¯exes,
thoracic epidural anaesthesia, in contrast to clonidine or
dexmedetomidine, can prevent bowel dysfunction after
abdominal surgery and improve gastrointestinal recovery.
Notably, high thoracic epidural anaesthesia can be used
safely in patients with bronchial hyper-reactivity.28
Although not directly compared with respect to cardiopro-
tection, lumbar epidural anaesthesia does not appear to offer
the same degree of protection. Serious complications
including post-dural puncture headache, neurologic injury,
and epidural haematoma (<1:100 000) with paraplegia may
be lower at the thoracic level. Collectively, thoracic epidural
anaesthesia is a unique treatment modality combining
effective pain relief with anti-adrenergic properties. It also
has the theoretical advantage of a lower cardiac complica-
tion rate in high-risk patients undergoing major surgery.41
Sympatho-modulatory therapies:
does it make sense to combine them?
Different anti-adrenergic therapies affect the autonomic
nervous system activity by different mechanisms and
accordingly differentially modulate haemodynamics
(Table 3). Thus, the question arises of whether these
treatment modalities should be combined to optimize
cardiac protection. Some combinations such as b-AAs or
a2-agonists with regional anaesthesia are occasionally used,
but have not been prospectively evaluated with respect to
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cardiac outcome and adverse effects. There is sparse clinical
and experimental data on ef®cacy and side-effects of
combined anti-adrenergic treatments. A comparison be-
tween thoracic epidural anaesthesia and b-AA on haemo-
dynamic parameters in conscious rats with acute myocardial
infarction revealed the following intriguing ®ndings.10
While thoracic epidural anaesthesia decreased left ven-
tricular end-diastolic pressure and systemic vascular resist-
ance remained unaffected, metoprolol in contrast increased
both parameters. Heart rate and cardiac output were
similarly decreased in both treatment regimens.
Importantly, induction of thoracic epidural anaesthesia
during maximal metoprolol treatment did not cause any
further haemodynamic changes (particularly no further
decline in arterial pressure). Similarly, in a clinical study
evaluating the effect of thoracic epidural anaesthesia (T1-
T12) on cardiovascular function in patients with coronary
artery disease receiving b-AAs, no further cardiac depres-
sion (decrease in arterial pressure and heart rate) occurred.76
From this, it can be speculated that the favourable
haemodynamic effects of thoracic epidural anaesthesia
may be synergistic with the documented life-saving effects
of b-AAs. Good haemodynamic tolerance of b-AAs com-
bined with epidural anaesthesia has been reported peri-
operatively in some clinical studies with small numbers of
patients.59 80 Intrathecal and oral clonidine prolongs
regional anaesthesia/analgesia but increases the incidence
of hypotension and bradycardia.19 Importantly, correction
of epidural anaesthesia-induced hypotension may provoke
transient myocardial ischaemia.67 Although the incidence of
bradycardia and hypotension may be signi®cantly increased
with the combination of regional anaesthetic techniques and
b-AAs/a2-agonists, there may be a net reduction in
ischaemic events and short- as well as long-term cardio-
vascular complications. However, this hypothesis must be
evaluated in future randomized clinical trials. A combin-
ation of b-AAs with a2-agonists appears to be less
meaningful except for a2-agonists being administered by
the intrathecal or epidural route. An increased incidence of
bradycardia and hypotension was reported previously for
mivazerol and dexmedetomidine alone,46 77 which may be
enhanced by co-administration of b-AAs. The combination
of b-AAs and a2-agonists is further complicated by the
following additional observations. Co-adminstration of
clonidine and sotalol annihilates the hypotensive effects
and rather increases arterial pressure, whereas propranolol
and atenolol potentiate the hypotensive and bradycardic
effects of clonidine in hypertensive patients.39 Notably,
atenolol even more profoundly reduces arterial pressure
than the non-selective propranolol. Administration of
prazosin (selective for a1-ARs) with clonidine further
reduces arterial pressure, but does not affect heart rate.
While clonidine is able to antagonize b-AA withdrawal,
b-AAs may be dangerous in treating a2-agonist withdrawal
(pressure raising effect of b-AAs during clonidine with-
drawal). Collectively, there is currently no evidence to
combine anti-adrenergic treatments in perioperative medi-
cine except for regional anaesthetic techniques with b-AAs
or mostly intrathecally administered a2-agonists. Because
of the simplicity, safety, and their profound impact on basic
physiological mechanisms in the heart, b-AAs remain the
®rst choice for prevention of perioperative adverse cardiac
events.
Conclusions
Selective stimulation of adrenergic receptor subtypes exerts
bene®cial or detrimental effects on the myocardium. Fine-
tuning of the complex adrenergic signalling mechanisms
may provide maximal cardioprotection. a2-Agonists non-
selectively decrease sympathetic tone, whereas b1-AAs may
be more selective. Unfortunately, no subtype-selective a2-
agonists are clinically available. Regional anaesthetic
techniques combine effective pain relief with inhibitory
but rather unpredictable effects on sympathetic nerve
activity. Administration of b1-AAs has been proven to be
most effective to prevent perioperative adverse cardiac
effects. However, there is currently no `sun and centre' in
the present armamentarium of perioperative sympatho-
modulatory treatments. Only a detailed understanding of the
complexities of adrenergic signalling and intracellular Ca2+
handling as well as of relevant genetic polymorphisms will
lead to novel more effective therapeutic strategies in
perioperative medicine.
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Table 3 Differential haemodynamic effects of individual, acutely established
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myocardial oxygen consumption; ¯=decreased; ­=increased; «=unchanged;
( )=variable
Parameter Treatment
b-AA a2-A LEA TEA SA
HR ¯ ¯ ¯/« ¯ ¯
BP ¯ (­)/¯ ¯ ¯ ¯
SVR (­) ¯ ¯ («) («)
Afterload ¯ ¯ ¯ («) («)
LVEDP ­ ­ ¯ ¯ ¯
CO ¯ ¯ ­ ¯ ¯
CVR « « «/(­) (¯) «/(­)
VO2 myocardium ¯ ¯ (­) ¯ (¯)
Arrhythmia ¯ (¯) « ¯ «
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